Beliefs and preferences regarding biological treatments for severe asthma

Creative Commons License

Bikov A., OĞUZÜLGEN İ. K., Baiardini I., Contoli M., Emelyanov A., Fassio O., ...Daha Fazla

WORLD ALLERGY ORGANIZATION JOURNAL, cilt.13, sa.7, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 7
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.waojou.2020.100441
  • Dergi Adı: WORLD ALLERGY ORGANIZATION JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, Directory of Open Access Journals
  • Anahtar Kelimeler: Severe asthma, Biological drug, Belief, Behavior, ADD-ON THERAPY, DOUBLE-BLIND, OMALIZUMAB, MEPOLIZUMAB, MULTICENTER, EFFICACY, SAFETY, LIFE
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers' specialty and experience.